Inflammatory Myofibroblastic Tumour of Head and Neck: A Systematic Review Plus Meta-Analysis

IF 1.9 4区医学 Q2 OTORHINOLARYNGOLOGY

Clinical Otolaryngology Pub Date : 2026-08-03 Epub Date: 2026-05-21 DOI:10.1111/coa.70120

Alireza Sharifi, Mohaddeseh Zojaji, Narges Badragheh, Mehran Jamali, Sahar Ghaedsharaf, Maryam Yaghoubi Hamgini, Mohammad E. Ghaffari, Samad Samadizadeh, Hassan H. Ramadan, Meghan T. Turner

{"title":"Inflammatory Myofibroblastic Tumour of Head and Neck: A Systematic Review Plus Meta-Analysis","authors":"Alireza Sharifi, Mohaddeseh Zojaji, Narges Badragheh, Mehran Jamali, Sahar Ghaedsharaf, Maryam Yaghoubi Hamgini, Mohammad E. Ghaffari, Samad Samadizadeh, Hassan H. Ramadan, Meghan T. Turner","doi":"10.1111/coa.70120","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Objectives</h3>\n \n <p>This systematic review with meta-analysis is aimed to examine clinical presentations, pathologic and imaging findings, treatment approaches, and prognosis of inflammatory myofibroblastic tumour.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>PubMed, Medline, Scopus, Cochrane Central Register of Control Trials, Web of Science, Google Scholar, and Embase were systematically searched up to February 2026. The search strategy was structured by a combination of relevant keywords and medical subheadings. This review adhered to Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) guidelines and Population, Intervention, Comparison, and Outcome (PICO) statement.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>A total of 22 studies, including 337 patients, met the inclusion criteria. Most of the tumours originated from the sinonasal space (40.1%, proportion = 163), and the maxilla bone and hypopharynx had the least frequency (0.3%, proportion = 1). The most prevalent manifestations were proptosis and facial pain/swelling. Regarding immunohistochemical findings, tumours were mostly positive for vimentin and SMA, while they were commonly negative for desmin, S-100, anaplastic lymphoma kinase, and CD34. Many patients were treated with surgical resection alone without any recurrence occurring. Recurrence occurred in 21.6% (proportion = 67). Metastases occurred in 8.8% (proportion = 8).</p>\n </section>\n \n <section>\n \n <h3> Conclusions</h3>\n \n <p>The diagnosis of head and neck inflammatory myofibroblastic tumour appears related to the presence of vimentin, SMA, desmin, anaplastic lymphoma kinase, CD34, and S-100 on immunohistochemistry. The enhancement pattern on computed tomography cannot help diagnosis, but absence of calcification may distinguish tumour from other differential diagnoses. Surgical resection with a free margin is the most common treatment approach. Metastasis and malignant transformation rarely occur in this tumour of the head and neck region.</p>\n </section>\n </div>","PeriodicalId":10431,"journal":{"name":"Clinical Otolaryngology","volume":"51 5","pages":"620-634"},"PeriodicalIF":1.9000,"publicationDate":"2026-08-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Otolaryngology","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/coa.70120","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/5/21 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"OTORHINOLARYNGOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Objectives

This systematic review with meta-analysis is aimed to examine clinical presentations, pathologic and imaging findings, treatment approaches, and prognosis of inflammatory myofibroblastic tumour.

Methods

PubMed, Medline, Scopus, Cochrane Central Register of Control Trials, Web of Science, Google Scholar, and Embase were systematically searched up to February 2026. The search strategy was structured by a combination of relevant keywords and medical subheadings. This review adhered to Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) guidelines and Population, Intervention, Comparison, and Outcome (PICO) statement.

Results

A total of 22 studies, including 337 patients, met the inclusion criteria. Most of the tumours originated from the sinonasal space (40.1%, proportion = 163), and the maxilla bone and hypopharynx had the least frequency (0.3%, proportion = 1). The most prevalent manifestations were proptosis and facial pain/swelling. Regarding immunohistochemical findings, tumours were mostly positive for vimentin and SMA, while they were commonly negative for desmin, S-100, anaplastic lymphoma kinase, and CD34. Many patients were treated with surgical resection alone without any recurrence occurring. Recurrence occurred in 21.6% (proportion = 67). Metastases occurred in 8.8% (proportion = 8).

Conclusions

The diagnosis of head and neck inflammatory myofibroblastic tumour appears related to the presence of vimentin, SMA, desmin, anaplastic lymphoma kinase, CD34, and S-100 on immunohistochemistry. The enhancement pattern on computed tomography cannot help diagnosis, but absence of calcification may distinguish tumour from other differential diagnoses. Surgical resection with a free margin is the most common treatment approach. Metastasis and malignant transformation rarely occur in this tumour of the head and neck region.

查看原文本刊更多论文

头颈部炎性肌成纤维细胞瘤：一项系统综述和荟萃分析。

目的：本系统综述结合荟萃分析，旨在探讨炎症性肌成纤维细胞瘤的临床表现、病理和影像学表现、治疗方法和预后。方法：系统检索PubMed、Medline、Scopus、Cochrane Central Register of Control Trials、Web of Science、谷歌Scholar和Embase，检索截止至2026年2月。搜索策略由相关关键字和医学小标题组合而成。本综述遵循系统评价和荟萃分析（PRISMA）指南和人群、干预、比较和结果（PICO）声明的首选报告项目。结果：共有22项研究，337例患者符合纳入标准。绝大多数肿瘤起源于鼻窦间隙（40.1%，比例= 163），上颌骨和下咽发生率最低（0.3%，比例= 1）。最常见的表现是突出和面部疼痛/肿胀。免疫组化结果显示，肿瘤大多呈vimentin和SMA阳性，而desmin、S-100、间变性淋巴瘤激酶和CD34阴性。许多患者仅行手术切除治疗，未见复发。复发率为21.6%（67例）。发生转移的占8.8%（比例= 8）。结论：头颈部炎性肌成纤维细胞瘤的诊断与免疫组化中vimentin、SMA、desmin、间变性淋巴瘤激酶、CD34、S-100的检测有关。计算机断层扫描上的增强模式不能帮助诊断，但没有钙化可以将肿瘤与其他鉴别诊断区分开来。手术切除游离缘是最常见的治疗方法。这种头颈部肿瘤很少发生转移和恶性转化。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Clinical Otolaryngology 医学-耳鼻喉科学

CiteScore

4.00

自引率

4.80%

发文量

106

审稿时长

>12 weeks

期刊介绍： Clinical Otolaryngology is a bimonthly journal devoted to clinically-oriented research papers of the highest scientific standards dealing with: current otorhinolaryngological practice audiology, otology, balance, rhinology, larynx, voice and paediatric ORL head and neck oncology head and neck plastic and reconstructive surgery continuing medical education and ORL training The emphasis is on high quality new work in the clinical field and on fresh, original research. Each issue begins with an editorial expressing the personal opinions of an individual with a particular knowledge of a chosen subject. The main body of each issue is then devoted to original papers carrying important results for those working in the field. In addition, topical review articles are published discussing a particular subject in depth, including not only the opinions of the author but also any controversies surrounding the subject. • Negative/null results In order for research to advance, negative results, which often make a valuable contribution to the field, should be published. However, articles containing negative or null results are frequently not considered for publication or rejected by journals. We welcome papers of this kind, where appropriate and valid power calculations are included that give confidence that a negative result can be relied upon.